ArticleCancer treatment reviews2019
Genomic profiling in pancreatic ductal adenocarcinoma and a pathway towards therapy individualization: A scoping review.
Article in Cancer treatment reviews, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 38 citations in OpenAlex.
- Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a GermlineJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020Trial
- Long-term disease control of GP2-NTRK1 fusion-positive pancreatic adenocarcinoma with liver metastases using sequential tyrosine receptor kinase inhibitors.Clinical journal of gastroenterology · 2026Article
- Advancing Precision Medicine in PDAC: An Ethical Scoping Review and Call to Action for IHC Implementation.Cancers · 2025Review
- Review
- Article
- The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy.Journal of experimental & clinical cancer research : CR · 2022Review
- Identification of LIPH as an unfavorable biomarkers correlated with immune suppression or evasion in pancreatic cancer based on RNA-seq.Cancer immunology, immunotherapy : CII · 2022Article
- Identification of New Regulators of Pancreatic Cancer Cell Sensitivity to Oxaliplatin and Cisplatin.Molecules (Basel, Switzerland) · 2022Article
- Ferroptosis-Related IncRNAs Are Prognostic Biomarker of Overall Survival in Pancreatic Cancer Patients.Frontiers in cell and developmental biology · 2022Article
- Exceptional Response to Olaparib and Pembrolizumab for Pancreatic Adenocarcinoma With GermlineJCO precision oncology · 2022Review
- Biomarkers for early detection of pancreatic cancer - miRNAs as a potential diagnostic and therapeutic tool?Cancer biology & therapy · 2021Review
- Targeting KRAS in Solid Tumors: Current Challenges and Future Opportunities of Novel KRAS Inhibitors.Pharmaceutics · 2021Review
- Review
- Article
- KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities.Journal of experimental & clinical cancer research : CR · 2020Review
- Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma.Cancer · 2020Article
- Epigenetic Landscape in Pancreatic Ductal Adenocarcinoma: On the Way to Overcoming Drug Resistance?International journal of molecular sciences · 2020Review
- Review
- New era for pancreatic endoscopic ultrasound: From imaging to molecular pathology of pancreatic cancer.World journal of gastrointestinal oncology · 2019Article
- Tumour response to TRK inhibition in a patient with pancreatic adenocarcinoma harbouring an NTRK gene fusion.Annals of oncology : official journal of the European Society for Medical Oncology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
contextPancreatic cancer (PDAC) is one of the most challenging cancers to treat with modest recent improvements in survival from new systemic therapies. There is growing interest in individualized therapy underpinned by somatic and germline genomic alterations.
objectiveA systematic review of data on therapies targeting somatic and germline alterations, and their downstream pathways in PDAC.
methodA systematic literature search was conducted using PRISMA guidelines to include relevant results published after January 1, 2008.
resultsA total of 71 relevant studies were included. We identified 36 studies targeting the KRAS-pathway, the most common being with MEK-inhibitor therapy. Twenty-two studies were identified that evaluated platinum-based chemotherapy and PARP inhibitors in patients with deleterious mutations in DNA damage repair genes and have shown encouraging results. Immunotherapy has demonstrated activity in patients with mismatch repair deficiency/microsatellite instability.
conclusionEvidence from translational and clinical research presents an exciting platform for genomic targeted therapy in PDAC. Validity for targeting BRCA with platinum and PARP inhibitors and microsatellite instability with immune therapy has been established, nonetheless, evidence for targeting the common driver oncogenes is lacking and much work is needed. Of importance is identifying the subgroup of KRAS -wild type PDAC (approximately 5%) where there is enrichment for targetable opportunities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.